Skip to content

Targovax announces appointment of Erik Digman Wiklund as CFO

05.January 2017 at 07:00:00 CET

Oslo, Norway, 5 January 2017: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that Erik Digman Wiklund has been appointed as the Company’s new Chief Financial Officer, and will take up this role in April 2017. The previous CFO, Oystein Soug, was appointed as Targovax’s CEO on 2 November 2016.

Erik joins from the nutraceutical company Aker Biomarine Antarctic AS, where he held the position as Director of Product Innovation. Prior to joining Aker Biomarine, Erik worked for Norwegian cancer biotechnology company Algeta ASA, and also has management consulting experience from the Pharma & Health Care practice of McKinsey & Company. Erik holds a PhD in Molecular Biology from Aarhus University, Denmark, and the Garvan Institute of Medical Research in Sydney, Australia.

Oystein Soug, CEO of Targovax commented: “We are delighted to announce the appointment of Erik as our new CFO. He has an impressive track record in commercial and operational roles in the biotechnology industry, combined with a strong scientific background. Erik’s breadth of expertise will be key as we approach a number of important milestones in 2017 and 2018 within our innovative clinical pipeline, designed to help patients own immune system to fight cancer.”

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624

Media and IR enquires:
Jan Petter Stiff – Crux Advisers (Norway)
Phone: +47 995 13 891

Julia Phillips/Simon Conway – FTI Consulting (International)
Phone: +44 20 3727 1000

Source: Targovax